Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 9;115(10):157-162.
doi: 10.3238/arztebl.2018.0157.

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor

Affiliations
Review

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor

Gregor Zaun et al. Dtsch Arztebl Int. .

Abstract

Background: 2-4% of newly diagnosed cases of malignant disease involve cancer of unknown primary (CUP). This mixed entity is one of the 6 most common types of malignant disease in Germany. Highly refined treatment strategies can now be offered to patients with CUP.

Methods: This review is based on pertinent publications retrieved by a selective search in PubMed with an emphasis on articles from the past decade. The current guidelines and recommendations of specialty societies were also considered in the evaluation.

Results: CUP most commonly manifests itself as metastases to the lymph nodes, lungs, liver, or bones. With the aid of imaging studies, including functional hybrid imaging and further medical examination, a primary tumor can be discovered in up to 40% of patients initially diagnosed with CUP. Immunohistochemistry guided by histomorphology often enables precise characterization of the lesion and can be supplemented, in selected cases, by molecular-genetic diagnostic evaluation. The most commonly detected types of primary tumor are cancers of the lung, pancreas, liver, and biliary system. For patients with local metastases, surgical resection or radiotherapy with curative intent is usually indicated, sometimes in the framework of a multimodal treatment concept. The median 2-year survival of patients with disseminated CUP is only 20%. For such patients, specific types of systemic therapy are recommended on the basis of the diagnostic characterization of the disease. Immune-modulatory antibodies can be effective, particularly in the treatment of CUP that has been characterized with biomarkers, but should still be considered experimental at present.

Conclusion: A combination of conventional and innovative diagnostic methods enables the provision of highly refined therapeutic strategies to patients with CUP who are undergoing treatment in interdisciplinary cancer centers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Detection of cervical lymph node filaments on the left side, and unobtrusive endoscopic and conventional morphological imaging in a 49-year-old female patient. a) The „maximum intensity projection“ (MIP) shows focal FDG uptake in the associated axial sections (b, PET; c, contrast medium CT; d, fused PET/CT) that was assigned to soft tissue asymmetry to the left above the hyoid bone. The primary tumor was then histopathologically confirmed and completely resected. CT, computed tomography; FDG, 2-fluoro-2-deoxy-D-glucose; PET, positron emission tomography
Figure 2
Figure 2
Important diagnostic antibodies and their algorithmic use (modified from [13]) (S100, MNF116, HMB45, etc. = antibody names)

Comment in

  • p16 Examination Is not Sufficient.
    Guntinas-Lichius O. Guntinas-Lichius O. Dtsch Arztebl Int. 2018 May 21;115(20-21):354. doi: 10.3238/arztebl.2018.0354a. Dtsch Arztebl Int. 2018. PMID: 29914615 Free PMC article. No abstract available.
  • Palliative Care Was not Considered.
    Thöns M. Thöns M. Dtsch Arztebl Int. 2018 May 21;115(20-21):354. doi: 10.3238/arztebl.2018.0354b. Dtsch Arztebl Int. 2018. PMID: 29914616 Free PMC article. No abstract available.

References

    1. Hübner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009;100:44–49. - PMC - PubMed
    1. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) (eds.) CUP Syndrom - Krebserkrankungen mit unbekanntem Primärtumor. Leitlinie: Stand 2014. www.onkopedia.com/de/onkopedia/guidelines/cup-syndrom-krebserkrankungen-... (last accessed on 26 January 2018)
    1. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428–1435. - PubMed
    1. National Comprehensive Cancer Network (NCCN) NCCN Guidelines for occult primary. www.nccn.org/professionals/physician_gls/f_guidelines. asp#occult(last accessed on 30 June 2017)
    1. European Society for Medical Oncology (ESMO) Cancers of unknown primary site: ESMO clinical practice guidelines. www.esmo.org/Guidelines/Cancers-of-Unknown-Primary-Site/Cancers-of-Unkno... (last accessed on 26 January 2018